Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

News and Events

For additional information, please contact info@trovagene.com. or call 1-858-952-7593

Please see write-up on Trovagene by CNA. Click Here to Read Article

Cardiff Oncology Chief Executive Officer, Dr. Mark Erlander, and Chief Financial Officer, James Levine will participate in the H.C. Wainwright Investment Conference September 13th - 15th, 2021....

Cardiff Oncology Chief Executive Officer, Dr. Mark Erlander, and Chief Financial Officer, James Levine will participate in the H.C. Wainwright Investment Conference September 13th - 15th, 2021....

Cardiff Oncology Chief Executive Officer, Mark Erlander, and Chief Financial Officer, James Levine, will participate in the H.C. Wainwright Global Investment Conference Monday, September 13th...